Orion Corporation is evaluating the possible outsourcing of its pharmaceutical production in Kuopio, part of its Global Operations function, to an entity outside Finland.

The basis for the possible outsourcing would be the lack of competitiveness of the Kuopio plant and the high investment needs of the plant, states the company.

The evaluation is due to the low competitiveness of the plant, low capacity utilisztion, increasing quality requirements in the pharmaceutical industry, and high investment needs. Volumes of the plant are low and due to the lack of competitiveness, outlook for growth is very limited. Therefore, the additional investment needed would not be justified.

The products currently manufactured in Kuopio would continue to be part of Orion’s product portfolio also in the future. The estimated time scope is that the plant would continue to operate until at least the summer of 2026.

The statutory negotiations include the entire personnel in operations and functions which support production in the Kuopio plant, altogether about 40 people.”

The company has today issued a negotiation proposal in accordance with the Co-operation Act within undertakings regarding the reorganisation of operations and possible personnel reductions. The statutory negotiations include the entire personnel in operations and functions which support production in the Kuopio plant, altogether about 40 people. Other employees working in the Kuopio plant are not impacted by the statutory negotiations.

Orion’s manufacturing plant in Kuopio specializes in liquids and self-care products. Among the most widely known of the products manufactured in Kuopio are nasal sprays, cough medicines, and ear drops.

Photo: Orion